Portal de investigación
Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Peña, M.
- Lazzari, L.
- Martinez, D.F.
- Ciceri, F.
- Pascual, M.J.
- Benzaquén, A.
- Piñana, J.L.
- Salas, M.Q.
- Nieto Vázquez, A.
- Español, I.
- Huguet, M.
- Bento, L.
- Sáez, A.J.
- Barba-Suñol, P.
- Filaferro, S.
- Carbonell-Asins, J.A.
- Peña, C.
- Mussetti, A.
- Greco, R.
Grupos
Abstract
Allogeneic haematopoietic cell transplantation (alloHCT) remains a potentially curative strategy for relapsed or refractory lymphoid malignancies, even in the post-chimeric antigen receptor T-cell and bispecific antibody era. While reduced-intensity conditioning regimens offer lower non-relapse mortality (NRM), relapse rates remain high, and optimal conditioning strategies in the setting of post-transplant cyclophosphamide (PTCy) prophylaxis remain undefined. In this retrospective, international multicentre study, the primary end-point was NRM. We compared treosulfan/fludarabine (Treo/Flu) versus thiotepa/busulfan/fludarabine (TBF) in 178 adults with lymphoid malignancies undergoing first alloHCT with PTCy and peripheral blood grafts. Three-year NRM was 14.0% with Treo/Flu versus 33.0% with TBF. On multivariate analysis, Treo/Flu was associated with significantly lower 3-year NRM (hazard ratio [HR] 0.44; 95% confidence interval [CI], 0.22–0.87; p = 0.018). Conditioning regimen was not independently associated with overall survival (OS) or progression-free survival (PFS), and relapse incidence was similar between regimens. Moderate to severe chronic graft-versus-host disease (GVHD) was higher with Treo/Flu (26.0% vs. 9.9%; HR 2.43; 95% CI, 1.09–5.43; p = 0.03), while GVHD-free/relapse-free survival (GFRS) was comparable. Findings were consistent in a prespecified propensity score-matched sensitivity analysis. These findings support Treo/Flu as a potentially safer reduced-toxicity conditioning option than TBF in the context of PTCy-based GVHD prophylaxis for lymphoid malignancies and warrant prospective validation. © 2026 British Society for Haematology and John Wiley & Sons Ltd.
Datos de la publicación
- ISSN/ISSNe:
- 0007-1048, 1365-2141
- Tipo:
- Article
- Páginas:
- 1017-1026
- DOI:
- 10.1111/bjh.70367
- PubMed:
- 41676905
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,677 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BRITISH JOURNAL OF HAEMATOLOGY WILEY
Documentos
- No hay documentos
Filiaciones
Keywords
- allogeneic haematopoietic cell transplantation; lymphoid malignancies; post-transplant cyclophosphamide; reduced-intensity conditioning; treosulfan/fludarabine
Campos de Estudio
Cita
Peña M,Lazzari L,Martinez DF,Ciceri F,BALAGUER A,SANZ J,Pascual MJ,Benzaquén A,Piñana JL,Salas MQ,Nieto A,Español I,Huguet M,Bento L,Sáez AJ,Barba P,Filaferro S,Carbonell JA,Peña C,Mussetti A,Greco R. Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study. Br. J. Haematol. 2026. 208. (3):p. 1017-1026. IF:3,600. (2).